- Home
- MYGN vs TSAT Comparison
MYGN vs TSAT Comparison
Compare MYGN & TSAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYGN
- TSAT
- Stock Information
- Founded
- MYGN 1991
- TSAT 1969
- Country
- MYGN United States
- TSAT Canada
- Employees
- MYGN N/A
- TSAT N/A
- Industry
- MYGN Biotechnology: In Vitro & In Vivo Diagnostic Substances
- TSAT Metal Fabrications
- Sector
- MYGN Health Care
- TSAT Industrials
- Exchange
- MYGN Nasdaq
- TSAT Nasdaq
- Market Cap
- MYGN 423.1M
- TSAT 394.3M
- IPO Year
- MYGN 1995
- TSAT 1996
- Fundamental
- Price
- MYGN $3.91
- TSAT $23.49
- Analyst Decision
- MYGN Hold
- TSAT
- Analyst Count
- MYGN 15
- TSAT 0
- Target Price
- MYGN $15.14
- TSAT N/A
- AVG Volume (30 Days)
- MYGN 1.3M
- TSAT 116.4K
- Earning Date
- MYGN 08-12-2025
- TSAT 08-06-2025
- Dividend Yield
- MYGN N/A
- TSAT N/A
- EPS Growth
- MYGN N/A
- TSAT N/A
- EPS
- MYGN N/A
- TSAT N/A
- Revenue
- MYGN $831,300,000.00
- TSAT $372,642,710.00
- Revenue This Year
- MYGN N/A
- TSAT N/A
- Revenue Next Year
- MYGN $6.64
- TSAT N/A
- P/E Ratio
- MYGN N/A
- TSAT N/A
- Revenue Growth
- MYGN 7.38
- TSAT N/A
- 52 Week Low
- MYGN $3.78
- TSAT $7.21
- 52 Week High
- MYGN $29.30
- TSAT $29.91
- Technical
- Relative Strength Index (RSI)
- MYGN 30.48
- TSAT 44.56
- Support Level
- MYGN $4.43
- TSAT $23.57
- Resistance Level
- MYGN $4.83
- TSAT $24.80
- Average True Range (ATR)
- MYGN 0.25
- TSAT 1.71
- MACD
- MYGN -0.10
- TSAT -0.65
- Stochastic Oscillator
- MYGN 9.32
- TSAT 13.36
About MYGN Myriad Genetics Inc.
Myriad Genetics Inc is a molecular diagnostics company that provides testing services designed to assess an individual's risk of developing a disease. The firm produces MyRisk, a 48-gene panel capable of identifying the elevated risk of developing 11 types of cancer. Other diagnostic products include BRACAnalysis CDx, the FDA-approved companion diagnostic for PARP inhibitors; GeneSight, which helps improve responses to psychotropic drugs for patients suffering from depression; and Prequel, a noninvasive prenatal test. Precise Oncology Solutions, launched in 2022, combines Precise Tumor with companion diagnostic and prognostic tests such as MyChoice CDx, Prolaris, and EndoPredict. The firm also offers pharma and biotech companies biomarker discovery and companion diagnostic services.
About TSAT Telesat Corporation and Class B Variable Voting Shares
Telesat Corp is a satellite operator, that provides its customers with mission-critical communications services. It operates in a single operating segment, in which it provides satellite-based services to its broadcast, enterprise, and consulting customers around the world. Geographically, it derives a majority of its revenue from Canada. It derives revenue from Broadcast, Enterprise, Consulting, and others.